PageHeader
About Us

Our Leadership Team

RareiTi™ was founded by leaders who envisioned and helped build the global managed access (i.e., expanded access, compassionate use, named patient) industry, along with experts in rare diseases, technology, data science, medicines management and home and remote care services.

Natalie Douglas
Co-founder, former CEO of IDIS and Healthcare At Home

Natalie started her healthcare career in the pharmaceutical industry at Janssen (J&J) and then as CEO built IDIS into the global market leader in delivering international managed access (i.e., expanded access, compassionate use, named patient) programs for physicians and the biopharmaceutical industry. In 2014 she joined Healthcare at Home as CEO, executing an operational turnaround. Natalie has served as Vice Chairman of Global Genes and currently holds a number of non-executive director and strategic advisory roles with healthcare technology companies. She is a former Health Investor Top 50 Executive (2015), a former EY regional Entrepreneur of the Year, recipient of a First Women award (2008) and Sunday Times Fast Track 100 (various).

Wendy White
Co-founder, former CEO of Siren Interactive and Chief Patient Officer of Vitrisa Therapeutics

Wendy is an innovative leader working for over 20 years in rare disease at the intersection of advocacy, technology and business. She founded, grew and transitioned Siren Interactive Corporation to Dohmen Life Science Services (now Eversana) as part of a vision to integrate patient level insights into the drug delivery continuum. She is the mother of a child with a rare disorder and publisher and co-author of Uncommon Challenges; Shared Journeys- Stories of Love, Hope, Community by Rare Disease Caregivers. Her background includes 4 consecutive years on the INC 5000 fastest growing companies list, recognition by PharmaVoice magazine in 2012 and 2015 as one of the 100 most inspiring people in the pharmaceutical industry culminating in a lifetime achievement Red Jacket award in 2017, and receipt of a Manny award from MadAd News for her work in rare disease.

Alex Evans, RN
Chief Executive Officer, Former Head of Clinical Nursing at AstraZeneca and Head of Nursing at Nutricia

Alex Evans has over 20 years of experience in the pharmaceutical and healthcare services industry. She is a registered clinician with senior level experience in clinical quality and evidence-based practice and a passionate leader of patient-centered care solutions. Alex’s career includes 13 years at Astra Zeneca and 5 years at Biogen Idec in both clinical and commercial roles. As an RN, Alex served as Head of Clinical Nursing at Astra Zeneca and Head of Nursing at Danone Advanced Medical Nutrition (Nutricia).

Alex joined RareiTi from Europe’s leading clinical home care provider, Healthcare at Home, where she served as Director of Quality and Governance and Regional Clinical Operations Director. She was responsible for delivering great commercial results through leading edge regulated patient support programs across a range of complex therapy areas and rare diseases.

Dr. Olivia Kessel
Chief Medical Officer, UK

Olivia brings global experience and two decades of practice as a physician and leader of patient-centric programs to her role as RareiTi’s Chief Medical Officer. Her clinical, commercial and systems expertise has been instrumental in developing RareiTi’s approach to and platform for delivering Expanded Access Programs. Olivia is an entrepreneur with experience in the delivery of digital health initiatives in Africa and is founder of EVOLVE – CARE, a digital health coaching company. Olivia was formally Director of Patient Services for Humira at Abbvie in Europe and Head of Medical Access for Gilead Sciences.

Heather Manna
Director of Regulatory Affairs

Heather Manna is a recognized expert in navigating the dynamic regulatory and compliance environment surrounding new drug approvals and is an operational leader with direct experience managing and directing the provision of services under Managed Access Programs. Heather brings valuable skills to RareiTi gained at global companies such as Sanofi-Aventis, Imclone (Eli Lilly), Takeda, Tesaro (GSK), IDIS, and Clinigen. She has a long track record of involvement with all facets of the regulatory submission process from CTA through approved NDA for leading pharmaceutical developers and has directed regulatory affairs and operations functions for EAP providers for more than a decade, serving as the key regulatory liaison to clients and acting as FDA liaison.

Lisa Johnson
Chief Financial Officer

With a background in risk management and mergers and acquisitions and with experience building the financial infrastructure necessary to support the launch and growth of an enterprise, Lisa brings more than 30 years of practice to her role at RareiTi.

Lisa grew her skills through many years and roles with Wells Fargo, ultimately serving as Midwest Division Manager and head of the bank’s Chicago leadership team.  Along with her husband Lamar, Lisa capitalized and built an architecture and design practice that grew to 30 professionals and positive cash flow within its first year.  She negotiated the sale of a majority interest in the firm and oversaw the integration with the operations of its new parent entity.  Lisa remains committed to solving the most pressing issues of her community through her work on the board of United Way of Metropolitan Chicago and as an active member of the Chicago Network, Women Leaders in Philanthropy and the Economic Club of Chicago.

Our Advisors

RareiTi’s leadership team is supported by an extraordinary group of advisors who provide global expertise and who stimulate innovation by connecting RareiTi to emerging trends and needs in the delivery of therapies to rare disease patients.

Jane Griffiths, PhD, Chair

A geneticist and distinguished global leader in healthcare and rare disease, Jane’s career with Johnson & Johnson included serving as Global Head of Actelion, a leading developer of orphan drugs, and as Company Group Chairman of Janssen EMEA. In addition to her deep experience in global commercialization and organizational strategy, she brings a personal belief in diversity as a driver of exceptional results. Jane serves as a Non-Executive Director of BAE Systems and Johnson Matthey, and has been recognized as Woman of the Year by HBA Europe and as a Top 100 Most Influential Medicine Makers by the Medicine Maker.

Martin Andrews

Martin brings over 35 years of pharmaceutical experience in medicine development and commercialization to RareiTi.  He spent many years in senior leadership roles at GlaxoSmithKline, leading numerous successful global product launches in pharmaceuticals and vaccines. During his career with GSK, he served as Senior Vice President of Rare Diseases and led the development and launch of the world’s first life-saving gene therapy for children, Strimvelis. Martin is a director of Freeline, a clinical-stage gene therapy company, Evox Therapeutics and Porton Biopharma, and he leads a consultancy specializing in rare disease, gene therapy and vaccine commercialization.

Craig DeLarge

Founder of The Digital Mental Health Project, Craig is a digital healthcare strategist and intrapreneur with core expertise in digital health and transformation built over a career in healthcare marketing and digital health roles with Takeda, MSD, Novo Nordisk, GSK, J&J, IMS Health (now IQVIA), and the (U.S.) National Alliance on Mental Illness. Craig brings global market expertise to his role as an advisor to RareiTi, having directed operations in both developed and emerging markets.

John Doux, MD

A graduate of Stanford Medical School and the Wharton School of Business at the University of Pennsylvania and a board-certified dermatologist, John has been actively involved for many years with companies developing and commercializing treatments for orphan populations as an analyst at Palo Alto Investors, a physician-led investment firm specializing in fundamental research. He also has served as a board director for companies focused on therapies for rare skin diseases.

Joff Masukawa

Joff is President of Diligentia, a life-sciences consultancy that develops commercialization strategies for manufacturers of rare orphan and specialty drugs, cell and gene therapies, and other novel emerging medical innovations. Previously, he served as Global Head of Government Relations and Public Affairs at Shire and Senior Director of US Managed Markets at Sanofi Genzyme. Mr. Masukawa is on the boards of Caregiver Action Network, the Center for Healthcare Innovation, and ICORD, the International Collaboration on Rare Diseases and Orphan Drugs, and is an advisor to America’s Health Foundation.

Our Value

Our Purpose

Our founders recognized that while the needs of biopharma companies, clinicians and patient communities have evolved significantly, managed access (i.e., expanded access, compassionate use, named patient) offerings haven’t kept pace.

The gap is especially striking in rare diseases. The number of investigational and approved medicines has grown from dozens to hundreds, and the number of identified rare conditions has expanded beyond 8,000 – yet the needs associated with each disease community and treatment modality are often quite distinct.

Managing access to therapies and care for rare disease patient requires a unique blend of global reach, personalized services, in-home and remote follow-up, and technology and real-world data and evidence to tie it all together.

RareiTi was created with these distinctive needs and capabilities in mind.

Our Reach

Global Operational Infrastructure

COVID-19 Response

The COVID-19 pandemic is having significant impact on clinical trials globally. Many trials face suspension or closure due to clinical priorities and the impact of social distancing and quarantine.

Clinical trial patients with a rare condition face great challenges; being part of a clinical trial when living with a rare condition can often be the only lifeline available, offering the chance to access novel therapies that could improve life enormously. During the pandemic, not being able to access novel therapies could have a major negative impact on health, disease progression and mortality. In addition, progress toward an approved therapy should not have to be completely stalled because of a lack of ability to collect relevant data.

Follow us on:

     

London  •  Chicago  •  New Jersey

©2021 RareiTi